Eli Lilly Canada Inc. ("Lilly") announced today that Ontario leads the way as the first province to add Olumiant® for severe ...

Nektar Therapeutics is expected to announce topline data from the REZOLVE-AA trial in December 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to rezpegaldesleukin for ...

RAAINBOW-2 is an international, double-blind, placebo-controlled Phase 3 study for the treatment of moderate to severe alopecia areata (AA) in at least 500 subjects. -- Cinainu is the first topical ...

FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo (Reuters) -Eli Lilly announced on Friday safety ...

Credit: SUN Pharma. Leqselvi is supplied as a tablet containing 8mg of deuruxolitinib. Prior to initiating treatment with Leqselvi, certain evaluations and immunizations are recommended. Leqselvi ™ ...

Nektar Therapeutics released data from a study of its rezpegaldesleukin drug, establishing proof-of-concept in patients with severe to very severe alopecia areata, a hair-loss condition. Mean percent ...

Baricitinib demonstrated significant efficacy in severe alopecia areata, with over 50% achieving substantial hair regrowth within a year. Early intervention and patient selection, particularly those ...

Hair loss is becoming more common for women in their 30s. The reason is more complicated than stress or styling habits.

Alopecia areata causes hair loss on the scalp or other body parts such as the eyebrows. New treatments like Olumiant offer hope for some people. This FDA-approved medicine works in unique ways to help ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Baricitinib maintained hair regrowth among adolescents ...

This article was reviewed by Sara Harcharik Perkins, MD. Key Takeaways: Folic acid (vitamin B9) supports healthy cell growth ...